844647-17-2

Usage

Uses

Used in Pharmaceutical Research:
2-Amino-4,5-dichloro-benzoic acid methyl ester is utilized as a building block in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Synthesis:
In addition to pharmaceutical research, 2-amino-4,5-dichloro-benzoic acid methyl ester is also employed in the synthesis of agrochemical compounds. This enables the creation of new products for agricultural use, such as pesticides and herbicides, to improve crop protection and yield.
Used in Organic Synthesis:
2-Amino-4,5-dichloro-benzoic acid methyl ester serves as an important intermediate in organic synthesis, allowing for the production of a wide range of chemical compounds with various applications across different industries.
Used in Research Laboratories:
This chemical compound is commonly found in research laboratories, where scientists conduct experiments and studies to explore its potential applications and properties further.
Used in Chemical Manufacturing Facilities:
2-Amino-4,5-dichloro-benzoic acid methyl ester is also utilized in chemical manufacturing facilities for the large-scale production of pharmaceutical and agrochemical compounds, contributing to the development and supply of these essential products.

Upstream product

• 67-56-1 methanol 
• 77423-12-2 6,7-dichloro-1,2-dihydro-3,1-benzoxazine-2,4-dione 
• 5900-58-3 2-amino-4-chloro-benzoic acid methyl ester 
• 20776-61-8 2-amino-4,5-dichloro-benzoic acid 
• 60695-93-4 methyl 4,5-dichloro-2-(chlorocarbonyl)benzoate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 15997-89-4 4,5-dichlorophthalimide 
• 145303-69-1 4,5-dichloro-2-methoxycarbonyl benzoic acid 
• 942-06-3 4,5-dichlorophthalic anhydride 
• 844647-19-4 C₉H₅Cl₂N₃O₃ 
• 40928-13-0 4-chloroisatoic anhydride 

Downstream Products

• 880347-54-6 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic acid methyl ester 
• 880347-55-7 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichlorobenzoic acid 
• 1297599-49-5 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichlorobenzoyl chloride 
• 20776-61-8 2-amino-4,5-dichloro-benzoic acid 
• 844647-21-8 4,5-dichloro-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester 
• 869550-60-7 methyl 2-acetamido-4,5-dichlorobenzoate 

Relevant academic research and scientific papers

NOVEL HISTONE METHYLTRANSFERASE INHIBITORS

The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.

ERBB/BTK INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compou

Hofmann-type rearrangement of imides by in situ generation of imide-hypervalent iodines(III) from iodoarenes

The Hofmann-type rearrangement of aromatic and aliphatic imides using a hypervalent iodine(III) reagent generated in situ from PhI, m-CPBA, and TsOH·H2O proceeded in the presence of a base in alcohol to provide anthranilic acid derivatives and amino acid derivatives in high yields, respectively. This reaction proceeds through a tandem reaction via alcoholysis followed by a Hofmann rearrangement promoted by the formation of an imide-λ3-iodane intermediate.

Protecting-group-free synthesis of a dual CCK1/CCK2 receptor antagonist

In our pursuit of an efficient, protecting-group-free synthesis of the dual CCK1/CCK2 receptor antagonist 1, we have developed chemoselective conditions for sulfonamide formation reaction in pure water and a PhNMe2 mediated carboxamide formatio

Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: Tuning of receptor selectivity and in vivo efficacy

In the previous article we demonstrated how certain CCK2R-selective anthranilic amides could be structurally modified to afford high-affinity, selective CCK1R activity. We now describe our efforts at modulating and optimizing the CCK1R and CCK2R affinitie

Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists

A 5,7-dichloro-3-phenyl-3-methyl-quinoline-2,4-dione (11a) has been identified in a random screen as a lead for 5-HT6 antagonist. During the lead optimization process, several analogs were synthesized and their biological activities were investigated. Within this series, several compounds display high binding affinity and selectivity for the 5-HT6 receptor. In particular, 3-(4-hydroxyphenyl)-3-methyl-quinoline-2,4-dione (12f) exhibits high affinity (Ki = 12.3 nM) for 5-HT6 receptor with good selectivity over other serotonin and dopamine (D1-D4) receptor subtypes. In a functional adenylyl cyclase stimulation assay, this compound exhibited considerable antagonistic activity (IC50 = 0.61 μM).

SULFONAMIDE COMPOUNDS

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same

The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders because of its excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors.

3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same

The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones , or a pharmaceutically acceptable salt thereof acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders because of its excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors.

Quinoxaline compounds

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.